• Explore /
  • Poster
  • / Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Abstract Poster

Authors

Marjorie Zauderer

Marjorie Glass Zauderer

Memorial Sloan Kettering Cancer Center, New York, NY

Marjorie Glass Zauderer , Peter Szlosarek , Sylvestre Le Moulec , Sanjay Popat , Paul Taylor , David Planchard , Arnaud Scherpereel , Thierry Jahan , Marianna Koczywas , Martin Forster , Robert B. Cameron , Tobias Peikert , Carly Campbell , Inbal Sapir , Alice McDonald , Coreen Oei , Alicia Clawson , Maria Roche , Dean A. Fennell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT02860286

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8515)

DOI

10.1200/JCO.2018.36.15_suppl.8515

Abstract #

8515

Poster Bd #

121

Abstract Disclosures

Similar Posters

First Author: Marjorie Glass Zauderer

First Author: Joanna S. Yi

First Author: Erel Joffe

Poster

2021 ASCO Annual Meeting

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

First Author: Dean Anthony Fennell